Navigation Links
The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
Date:4/8/2009

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer

SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results from a Phase 1/2 trial of MYDICAR(R) (AAV1/SERCA2a), a genetically targeted enzyme replacement therapy for advanced heart failure, in the April 2009 issue of the Journal of Cardiac Failure. The CUPID clinical trial demonstrated acceptable safety and produced quantitative evidence of biological activity across a number of parameters important for assessing heart failure. MYDICAR is designed to restore levels of an enzyme, SERCA2a, known to play a key role in the progression of heart failure. Repairing this molecular defect in animal studies has been shown to reverse the disease and restore cardiac function.

"Despite important therapeutic advances in pharmacologic and device therapies, the prognosis of patients with chronic heart failure remains extremely poor. Moreover, heart transplantation and the use of implantable assist devices are considered only in the later stages of the disease, and access to such therapies is restricted to a fraction of patients in need," said Brian E. Jaski, M.D., Medical Director of Advanced Heart Failure, Sharp Memorial Hospital, San Diego Cardiac Center, San Diego, a principal investigator on the study, and a lead author of the publication. "The CUPID trial is the first to attempt to rescue a failing heart by replacing an enzyme known to play a critical role in normal cardiac muscle cell activity. Our objective is not only to improve the symptoms of heart failure, but restore physiologic function and reverse the severity of the disease in this chronic patient population."

The results of this study include data from the Phase 1 portion of this ongoing Phase 1/2 study for Cohorts 1 a
'/>"/>

SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
2. NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations
3. American Association for Cancer Research (AACR) Deploys Collexis Reviewer Finder and Journal Dashboard Applications
4. Evidence of Ancient Hot Springs on Mars Detailed in Astrobiology Journal
5. Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
6. Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award
7. Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience
8. BioSpace Partners with Journal of Visualized Experiments (JoVE) to Offer Peer-Reviewed Scientific Video Content on BioSpace.com
9. Tips from the journals of the American Society for Microbiology
10. Elsevier Introduces The American Journal of Medicine Blog
11. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , , SAN MATEO, Calif., Nov. 24 /PRNe...X ), a biopharmaceutical company focused on develo...rapies, announced today that Anthony DiTonno, Pres... present at the 21st Annual Piper Jaffray Health C...he New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... , , , Primary efficacy endpoint has ...ecurrent endometrial cancer, , QUEBEC CITY, N...nc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a ...ine therapy and oncology, today announced positive...ted cytotoxic peptide conjugate, AEZS-108 (formerl...
(Date:11/24/2009)... , , REDWOOD CITY, Calif., Nov. 24 /PRN...: GHDX ) today announced that Randy Scott, Genomi... 21st Annual Piper Jaffray Health Care Conference ...0:00 a.m. ET. ,, To access the live and subseq... the Investor Relations section of Genomic Health,...
(Date:11/24/2009)... , , SEATTLE, Nov. 24 /PRNewswire-Fir...nd MTA: CTIC) management will present at the 21st ...onference will be held December 1-2, 2009, at the ... Tuesday, December 1 at 11:00 a.m. Eastern Time in...,s presentation will be available at www.cellther...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...f Standards and Technology (NIST) have made the fi...sion and collapse of thin polymer films used in th...ts a matter of only a couple of nanometers, but it...eneration chip manufacturing. The NIST measurement...nto the complex chemistry that enables the mass pr...
... CARLSBAD, Calif., Dec. 12 Genoptix, Inc.,(Nasdaq...er, today reported,revenues of $16.2 million for t...ase of 134% over revenues of $6.9 million for the ...ed September 30, 2007, the Company reported,revenu...nues of $16.2,million for the comparable period in...
...Inc. (Nasdaq: ARNA ) today announced that Phillip...to its board of directors. Mr. Schneider and Mr.,W...rectors and bring,significant financial and biotec...nce to Arena,s board of directors. Arena,s board a... and Mr. Woods to its Corporate Governance,and Nom...
Other Biology Technology:New paper reveals nanoscale details of photolithography process 2Genoptix Reports Strong Financial Results For Third Quarter 2007 2Genoptix Reports Strong Financial Results For Third Quarter 2007 3Genoptix Reports Strong Financial Results For Third Quarter 2007 4Genoptix Reports Strong Financial Results For Third Quarter 2007 5Genoptix Reports Strong Financial Results For Third Quarter 2007 6Genoptix Reports Strong Financial Results For Third Quarter 2007 7Genoptix Reports Strong Financial Results For Third Quarter 2007 8Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 2Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 3
(Date:11/23/2009)...- More than 160 participants gathered this week fo...ES INITIATIVE conference. This year,s topic, "Synt...eers, and medical researchers to explore the engin...the emerging field of synthetic biology. , Bonni...inceton University and this year,s conference chai...
(Date:11/23/2009).... A new study provides "incontrovertible evidence...island of Sumatra about 73,000 years ago deforeste... epicenter, researchers report. , The volcano ej...o the atmosphere, leaving a crater (now the world,...ng and 35 kilometers wide. Ash from the event has ...
(Date:11/23/2009).... - By producing some of the highest resolution im...ientists have a deeper understanding how biomolecu...may lead to a new treatment for kidney stones usin... the Nov. 23 online edition of the journal Procee...es how peptides interact with mineral surfaces by ...
Breaking Biology News(10 mins):Synthetic biology offers new opportunities for interdisciplinary collaboration 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3ALPCO Launches GLP 1 28Active 7 36 29 and 287 36 and 9 36 29 ELISA Kits 57959 1ALPCO Launches GLP 1 28Active 7 36 29 and 287 36 and 9 36 29 ELISA Kits 57959 2New multi use device can shed light on oxygen intake 57958 1New multi use device can shed light on oxygen intake 57958 2To regenerate muscle cellular garbage men must become builders 57953 1To regenerate muscle cellular garbage men must become builders 57953 2
...ss and what does it do? It stops eating. Humans sh...stress they often head for the refrigerator, produ...s, which are normally solitary, are placed in a gr...ientists at the Center for Behavioral Neuroscience... a model for human stress-induced obesity. They wa...
...st a few calories from the daily diet can do more ... help lessen the effects of aging. , Scientists fr...have found that eating a little less food and exer... even reverse aging-related cell and organ damage ... the journal Antioxidants and Redox Signaling, bui...
... way insects, plants and animals overcome engineer...nergy, according to new research published in the ... engineering difficulties, such as lifting a load ... of man-made technologies manipulate energy, often...he problem. , However, new research which has com...
Other Biology News:Just like us, social stress prompts hamsters to overeat, gain weight 2Just like us, social stress prompts hamsters to overeat, gain weight 3Just like us, social stress prompts hamsters to overeat, gain weight 4Cutting calories slightly can reduce aging damage 2Cutting calories slightly can reduce aging damage 3Copying nature could save us energy, study shows 2
Coverslips for Microarrays from GE Healthcare, formerly Amersham Biosciences
Argarase from BioVision
Rabbit Anti-HALOPERIDOL Polyclonal Antibody, Unconjugated from AbD Serotec
...tain stiffness in liquids, protect against acciden...segments on each strip have chemically bonded dyes...or charts provide clear comparison. Full-range str...100; each strip is approximately 1/4 x 3 in. (6 x ...
Biology Products: